Follow-up study of HER2-positive breast cancer after pre-surgery treatment
Part of Cancer, Skin clinical trials.
This study follows patients with HER2-positive breast cancer who received chemotherapy and a targeted drug (trastuzumab) before surgery but did not have a complete response. Researchers want to understand which follow-up treatments work best to prevent cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be HER2-positive (a specific protein marker confirmed by lab tests)
- You must have received at least 6 cycles of chemotherapy before surgery, including at least 4 cycles of taxane-based chemotherapy
- You must have received at least 4 cycles of trastuzumab (Herceptin or similar targeted drug) before surgery
- You must have had surgery to remove the breast cancer, with cancer cells still found in the breast or lymph nodes after pre-surgery treatment
- Your hormone receptor status must be documented in your medical records
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This trial tests whether giving trastuzumab before surgery can improve outcomes for people with HER2-positive early breast cancer. Trastuzumab is a targeted medicine that helps treat HER2-driven cancer before the tumor is removed.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.